Inhibition of the Wnt/β-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate cancer

Enzalutamide is a second-generation nonsteroidal antiandrogen clinically approved for the treatment of castration-resistant prostate cancer (CRPC), yet resistance to endocrine therapy has limited its success in this setting. Although the androgen receptor (AR) has been associated with therapy failur...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Res
Hlavní autoři: Zhang, Zhuangzhuang, Cheng, Lijun, Li, Jie, Farah, Elia, Atallah, Nadia M., Pascuzzi, Pete E., Gupta, Sanjay, Liu, Xiaoqi
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6004251/
https://ncbi.nlm.nih.gov/pubmed/29700003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-3006
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky